Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Karyopharm Therapeutics Inc.

Eilean Therapeutics is a small molecule oncology drug discovery company that develops pan-variant therapies for hematologic malignancies targeting major drivers of cancer resistance.

Eilean Therapeutics

Immunome is a clinical-stage targeted oncology company focused on developing targeted therapies to improve outcomes for cancer patients. The company has an innovative portfolio of therapeutics, including antibody-drug conjugates and treatments for desmoid tumors.

Immunome

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company that focuses on pioneering novel cancer therapies. The company is engaged in the discovery, development, and investigation of cancer treatments, particularly those addressing high unmet medical needs.

Metric
Company Name	Karyopharm Therapeutics Inc.	Eilean Therapeutics	Immunome
Symbol	KPTI
MSH ID	COM:KARYOPHARM	COM:EILEANTHER	COM:IMMUNOME
Market	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Pharmaceuticals
Country	US	US	US
Stage
Employee Count	325
Website	karyopharm.com	eileanther.com	immunome.com
LinkedIn			immunome-inc-
Founders

Metric
Market Cap	107.99M
Enterprise Value
Monthly Web Traffic	2.40K
Web Traffic Growth	-0.31
Valuation
Raised Capital

Metric
Revenue	146.03M
Revenue (LTM)
Revenue (NTM)
Gross Profit	140.56M
EBITDA	-129.01M
Operating Income	-129.54M
Net Income	-143.10M
EPS	-1.25
Diluted EPS	-1.25
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.97
Operating Profit Margin	-0.89
EBITDA Margin	-0.88
Net Profit Margin	-0.62
Return on Equity	1.62
Return on Assets	-0.42
Return on Capital Employed	-0.76

COM:KARYOPHARM

Karyopharm Therapeutics Inc.

Last Close

0.78

22/11 21:00

Market Cap

107.99M

Beta: -

Volume Today

500.06K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-1.16
P/B Ratio	-1.61
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.11
EV Multiple	0.37

Metric
Days Sales Outstanding	94.89
Days Payables Outstanding	64.65
Days Inventory Outstanding	221.30
Operating Cycle	308.98
Cash Conversion Cycle	136.96
Asset Turnover	0.69

Metric
Operating Cash Flow	-92.72M
Free Cash Flow	-92.72M
Cash Flow to Debt	-0.53
Operating Cash Flow/Sales	-0.63
Free Cash Flow Yield	-0.43

Metric
Cash & Equivalents	52.89M
Accounts Receivable	20.12M
Inventory	3.04M
Goodwill
Debt to Capitalization	31.19
Debt to Assets	0.64
Current Ratio	3.98
Quick Ratio	3.56

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.13
R&D to Revenue	0.89
SG&A to Revenue	0.72